In-Silico evaluation of Anti-Leishmanial compounds of selected pharmacophore
Abstract
In this study, out of sixteen compounds, only thirteen compounds have shown hydrogen bonding with the modeled cathepsin B protein of L donovani, remaining compound (C1D13416238, Posaconazole. and CID 6082033) did not show any hydrogen bonding with ligands. So, these 13 compounds which show hydrogen bonding with modeled protein could be considered as most potent lead compounds having inhibitory activity at either promastigote stage or amastigote stage of Leishmania donovani. Few compounds demonstrated better docking score to either AutoDock4.0 or GOLD v2.l but some compound did not show any hydrogen bonding with modeled protein in either docking software tool. Thus, it could be concluded that generated experimental compounds could have potential as pharmacological tool against Visceral Leishmaniasis.
Keywords: Cysteine Protease, Vinyl Hydrazide, Antileishmanial Drugs, Licochalcone, Visceral Leishmaniasis.
DOI
https://doi.org/10.22270/jddt.v8i6-s.2119References
Chappuis F et al., “Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?,” Nat. Rev. Microbiol., 2007; 5(11):S7.
Lukeš J, Skalickỳ T, Tỳč J, Votỳpka J, Yurchenko V, “Evolution of parasitism in kinetoplastid flagellates,” Mol. Biochem. Parasitol., 2014; 195(2):115–122.
Andersen JF, Pham VM, Meng Z, Champagne DE, Ribeiro JM, “Insight into the Sialome of the Black Fly, Simulium vittatum,” J. Proteome Res. 2009; 8(3):1474–1488.
W. H. O., Leishmaniasis. Fact sheet. Updated March 2016. 2016.
Pearson RD, de Queiroz Sousa A, “Clinical spectrum of leishmaniasis,” Clin. Infect. Dis., 1996; 1–11.
Chang CS, Chang KP, “Heme requirement and acquisition by extracellular and intracellular stages of Leishmania mexicana amazonensis,” Mol. Biochem. Parasitol., 1985; 16(3):267–276.
Petersen CA, Greenlee MHW, “Neurologic manifestations of Leishmania spp. infection,” J. Neuroparasitology, 2011; 2.
Published
Abstract Display: 391 
PDF Downloads: 532 How to Cite
Issue
Section
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.